Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III single-blind randomized trial of cetirizine hydrochloride 0.24% ophthalmic solution in Chinese patients with allergic conjunctivitis
CTR20201995Phase 3Completed
- Sponsor
- Eyevance Pharmaceuticals
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cetirizine in allergic conjunctivitis (AC), sponsored by Eyevance Pharmaceuticals. Started Oct 2020; status: completed.
02
Drugs
cetirizine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on CTR20201995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201995.